UNSPSC 51111859: Mecasermin

This classification denotes a therapeutic insulin-like growth factor, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7GR9I2683O. European Medicines Agency schedules Mecasermin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08672MIG. Mecasermin generally arises in the molecular formula C331H512N94O101S7.

The term MECASERMIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 6, no, 3 1992, list 32.) MECASERMIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule Mecasermin under HS 29371900 and SITC 54154. SMILES:. As of Q4 2014, MECASERMIN remains the US FDA Preferred Term for this commodity.. Mecasermin bears US NLM identifiers UMLS ID C0904505 and NCI Concept Code C2262.

UNSPSC 51111859 Mecasermin is a Commodity code for a specific pharmaceutical product, but state and local procurement activity under this code centers on broader generic multi-source pharmaceuticals and over-the-counter products through cooperative purchasing arrangements. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) represents the primary recent issuing body, administering agreements for multiple jurisdictions including state facilities and participating local government entities across states such as Minnesota and Oregon. The work involves pharmaceutical manufacturers supplying products through established wholesaler networks, with vendors required to provide comprehensive product information indexed to National Drug Codes (NDCs), maintain compliance with current Good Manufacturing Practices (cGMP) and the Drug Supply Chain Security Act (DSCSA), and offer flexible pricing structures including flat pricing, net price formats, and WAC-minus options. Vendors must establish contractual relationships with at least two of three authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health, and Morris & Dickson Co., LLC) and carry substantial insurance coverage including commercial general liability of $5,000,000 per occurrence.

MMCAP's RFP (solicitation S1070000015802) issued January 20, 2026 with responses due March 26, 2026 represents the primary recent opportunity under this code. The solicitation establishes two-year contracts with optional extensions, with evaluation weighted heavily toward price competitiveness (75 percent) and administrative compliance (10 percent combined for fixed pricing and data format requirements); all products must be available in the marketplace by May 15, 2026, with agreements effective July 1, 2026. Vendors are subject to a 3 percent administrative fee on all contract purchases and performance penalties ranging from $200 to $1,500 per violation. No specific set-aside designations or disadvantaged-enterprise restrictions were identified in the available documentation.